Table 6.

Performance of novel multiplex real-time PCR assay compared to Sanger sequencing in all Clinical specimens.

Pathogene	Sensitivity (95% CI)	Specificity (95% CI)	Kappa value	Kappa P	McNemer P
Chlamydia trachomatis	99.72% (99.25–100.20%)	96.26% (95.54–97.98%)	0.974	<0.001	0.375
Neisseria gonorrhoeae	100% (100–100%)	96.37% (96.51–98.23%)	0.980	<0.001	1.000
Trichomonas vaginalis	100% (100–100%)	99.92% (99.77–100.07%)	0.986	<0.001	1.000
HSVI	97.94% (96.59–98.29%)	99.77% (99.51–100.03%)	0.948	<0.001	0.625
HSVII	98.82% (98.24–99.40%)	99.76% (99.49–100.02%)	0.975	<0.001	0.625
Mycoplasma genitalium	96.30% (95.28–97.31%)	100% (100–100%)	0.981	<0.001	1.000
Ureaplasma urealyticum	92.86% (91.47–94.24%)	99.56% (99.21–99.92%	0.942	<0.001	0.096
Ureaplasma parvum	96.50% (95.52–97.49%)	99.14% (98.64–99.64%	0.959	<0.001	0.043
Mycoplasma hominis	91.06% (89.52–92.59%)	100% (100–100%)	0.949	<0.001	0.001